Pinocembrin

Pinocembrin

SCHEMBL2484359

O.O=C1CC(c2ccccc2)Oc2cc(O)cc(O)c21

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO

The experimentally established mechanism targets of Pinocembrin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 known ✓ O00255 2/20 0.97
ESR1 known ✓ P03372 1/20 0.80
DPP4 known ✓ P27487 1/20 0.80
GSK3B known ✓ P49841 1/20 0.80
ESR2 known ✓ Q92731 1/20 0.80
PTGS1 known ✓ P23219 1/20 0.65
PTGS2 known ✓ P35354 1/20 0.65
CYP19A1 P11511 7/20 0.97
CYP3A4 P08684 5/20 0.97
CYP1A1 P04798 4/20 0.97
CYP1A2 P05177 4/20 0.97
CYP1B1 Q16678 4/20 0.97
CYP2C19 P33261 3/20 0.97
HSD17B10 Q99714 3/20 0.97
MAPT P10636 3/20 0.97
CYP2C9 P11712 2/20 0.97
KMT2A Q03164 2/20 0.97
CYP2D6 P10635 1/20 0.97
TTR P02766 4/20 0.80
PSMB5 P28074 3/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pinocembrin SCHEMBL10026578 0.99 CYP19A1 (1.00) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
(R)-Pinocembrin SCHEMBL10080882 0.99 CYP19A1 (1.00) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
Pinocembrin SCHEMBL30186539 0.99 CYP19A1 (1.00) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
Pinocembrin SCHEMBL291899 0.99 CYP19A1 (1.00) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
Pinocembrin SCHEMBL2232882 0.96 CYP19A1 (0.95) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
Pinocembrin SCHEMBL3437711 0.92 CYP19A1 (0.88) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
Naringenin SCHEMBL30267460 0.90 CYP19A1 (0.97) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
Pinocembrin SCHEMBL17651823 0.89 CYP19A1 (0.81) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
Naringenin SCHEMBL1333765 0.89 CYP19A1 (0.81) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1
Naringenin SCHEMBL72954 0.89 CYP19A1 (0.81) CYP19A1CYP3A4CYP1A1CYP1A2CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106963755-A Application of the pinocembrin in demyelinating disease medicine is prepared 中国人民解放军第二军医大学 2017-07-21 CN claimed
CN-102548626-A Use of racemates of pinocembrin in preparing medicaments for treating stroke CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD 2012-07-04 CN claimed
EP-2377529-A1 USE OF RACEMATES OF PINOCEMBRIN IN PREPARING MEDICAMENTS FOR TREATING STROKE CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2011-10-19 EP claimed
US-20110245334-A1 USE OF RACEMATES OF PINOCEMBRIN IN PREPARING MEDICAMENTS FOR TREATING STROKE CSPC Zhonggi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. (CN) 2011-10-06 US claimed
CN-101744806-A Application of pinocembrin raceme in preparation of medicals for cerebral apoplexy ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD 2010-06-23 CN claimed
CN-106963755-B Application of pinocembrin in preparation of drugs for treating demyelinating diseases 中国人民解放军第二军医大学 2020-01-10 CN disclosed
CN-106963755-B Application of pinocembrin in preparation of drugs for treating demyelinating diseases 中国人民解放军第二军医大学 2020-01-10 CN disclosed
CN-106963755-A Application of the pinocembrin in demyelinating disease medicine is prepared 中国人民解放军第二军医大学 2017-07-21 CN disclosed
CN-106963755-A Application of the pinocembrin in demyelinating disease medicine is prepared 中国人民解放军第二军医大学 2017-07-21 CN disclosed
CN-101744806-B Application of pinocembrin raceme in preparation of medicals for cerebral apoplexy CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD 2012-09-12 CN disclosed
CN-101744806-B Application of pinocembrin raceme in preparation of medicals for cerebral apoplexy CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD 2012-09-12 CN disclosed
CN-102548626-A Use of racemates of pinocembrin in preparing medicaments for treating stroke CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD 2012-07-04 CN disclosed
EP-2377529-A1 USE OF RACEMATES OF PINOCEMBRIN IN PREPARING MEDICAMENTS FOR TREATING STROKE CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2011-10-19 EP disclosed
EP-2377529-A1 USE OF RACEMATES OF PINOCEMBRIN IN PREPARING MEDICAMENTS FOR TREATING STROKE CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2011-10-19 EP disclosed
US-20110245334-A1 USE OF RACEMATES OF PINOCEMBRIN IN PREPARING MEDICAMENTS FOR TREATING STROKE CSPC Zhonggi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. (CN) 2011-10-06 US disclosed
US-20110245334-A1 USE OF RACEMATES OF PINOCEMBRIN IN PREPARING MEDICAMENTS FOR TREATING STROKE CSPC Zhonggi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. (CN) 2011-10-06 US disclosed
CN-101744806-A Application of pinocembrin raceme in preparation of medicals for cerebral apoplexy ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD 2010-06-23 CN disclosed
CN-101744806-A Application of pinocembrin raceme in preparation of medicals for cerebral apoplexy ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD 2010-06-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245334-A1 USE OF RACEMATES OF PINOCEMBRIN IN PREPARING MEDICAMENTS FOR TREATING STROKE CROCC, PNN, ZMPSTE24 MEN1 3524/4885ESR1 4790/4885DPP4 552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.